From: Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
Best response
Trifluridine/tipiracil plus bevacizumab group
Trifluridine/tipiracil monotherapy group
P
N = 60
%
N = 66
PR
3
5.0
1
1.5
SD
29
48.3
43.9
PD
25
41.7
34
51.5
NE
2
3.0
ORR
0.346
DCR
32
53.3
30
45.5
0.476